- Optovue the global leader in the development of optical coherence tomography ( OCT ) and OCT angiography ( OCTA ), today announced the retirement of renowned industry veteran John Hawley, the company’s senior vice president of global sales. Hawley will retire on July 1, 2018 and remain with Optovue in an advisory role. Prominent industry veteran John Hawley retires from Optovue. Tweet this “For the past 10 years, I have worked side-by-side with John as we built Optovue from a fledgling start-up to the global company we are today,” said Jay Wei, founder and chief executive officer of Optovue. “As a result of ...

Teledyne Technologies Incorporated (NYSE:TDY) announced today that Teledyne DALSA and Teledyne e2v were awarded Gold and Silver 2018 Innovator Awards from Vision Systems Design . This annual program celebrates innovative technologies, products and systems found in the machine vision and image processing market. Winners were selected by a panel of judges comprised of systems integrators, consultants and academics with years of experience in specifying, designing and configuring image processing and machine vision systems. Teledyne DALSA won Gold-level honors for its Linea CMOS multi-channel line scan machine vision camera. Used in advanced machine vision and automated inspection systems, Teledyne DALSA’s ...

Optovue , the global leader in the development of optical coherence tomography ( OCT ) and OCT angiography ( OCTA ), will highlight its AngioVue® Essential OCTA capability for general ophthalmology, along with its suite of advanced eye care technology at the upcoming American Academy of Ophthalmology Annual Meeting (AAO), Nov. 11-14 in New Orleans. The company will also host an OCT and OCT Angiography Interpretation Lab offering small group sessions, led by industry experts, for learning the fundamentals of OCTA in retinal disease and glaucoma, as well as epithelial thickness mapping in refractive practice. And, in celebration of three years of OCT Angiography, Optovue ...

The Glaucoma Module Premium Edition for SPECTRALIS provides a comprehensive analysis of the optic nerve head, retinal nerve fiber layer, and ganglion cell layer by precisely matching unique scan patterns to the fine anatomic structures relevant in glaucoma diagnostics. By means of a new proprietary technology called the Anatomic Positioning System, the module creates an anatomic map unique to each patient’s eye using two fixed, structural landmarks: the center of the fovea and the center of Bruch’s membrane opening. All subsequent scan protocols are automatically oriented according to each eye’s unique anatomic map, enabling a precise examination ...

NinePoint Medical, Inc., a transformative medical device company pioneering the use of an advanced imaging platform for gastrointestinal applications, announced today that it has completed the primary phase of its Registry for High Resolution Optical Imaging of the Esophagus Using the NvisionVLE ® Imaging System. Results from the registry’s interim analysis will be presented in 11 scientific abstracts accepted to Digestive Disease Week ® (DDW) 2016, to be held May 21-24 in San Diego, California.

At the 2015 Annual Meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, ZEISS announces innovations for clinical excellence and practice performance in ophthalmology. In the field of retina and glaucoma, doctors can expand their treatment option based on the innovative ZEISS AngioPlex OCT Angiography that provides three-dimensional representations of the retina and the choroid, eliminating the risk of adverse reactions caused by injections into the eye: Blood vessels can now be displayed using optical coherence tomography (OCT). Furthermore, two new fundus cameras offer more detailed views in the diagnosis and follow-up of eye diseases. Cataract surgeons can ...

D ZEISS Medical Technology announces that its AngioPlex OCT Angiography is the first such technology to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA). “OCT angiography ushers in a new era in the evaluation of the retina in diabetic retinopathy and macular degeneration” With a single additional OCT scan that takes just seconds on the CIRRUS HD-OCT system from ZEISS, ophthalmologists can now utilize optical coherence tomography (OCT) images to assess the blood vessels (vasculature) of the retina at a depth and clarity never available before. AngioPlex OCT Angiography delivers high-resolution, depth-resolved visualization of the ...

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that a new article e-published in May 2015 in The Journal of Catheterization and Cardiovascular Intervention highlights the mechanical effect of orbital atherectomy (OA) and rotational atherectomy (RA) in treating heavily calcified coronary lesions. ” The article, titled “Optical Coherence Tomography Assessment of the Mechanistic Effects of Rotational and Orbital Atherectomy in Severely Calcified Coronary Lesions,” details results from a study led by Dr. Annapoorna Kini, Professor of Cardiology at the Mount Sinai Hospital and Icahn School of Medicine, and Director of The Cardiac Catheterization Lab at Mount Sinai Hospital. Said study co-investigator ...

Dr. Sheldon Feldman and Dr. Fatih Balci study intraductal approaches to breast cancer. They are currently investigating the effectiveness of optical coherence tomography (OCT), which is used in cardiology to look at blood vessels from the inside using light instead of sound (as an ultrasound does) to create three-dimensional images. OCT may be able to identify early changes in the breast duct before ductal carcinoma in situ (DCIS) or cancer forms. This consortium received $17,000 to study whether it is feasible to use OCT to distinguish different types of breast cells and tissues and whether OCT can show features ...

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Barry Gertz, MD, PhD, and Jay S. Duker, MD, to the company’s Board of Directors. Each of these new Board members brings more than 25 years of experience that is relevant to Eleven’s progress in advancing its pipeline of innovative therapies for ocular diseases. “We are excited to add these two highly accomplished industry and academic leaders to round out our Board. Their strategic support and guidance will be key as we continue to advance our ...

Engaged Capital, an investment firm specializing in small and mid-cap North American equities and beneficial owner of approximately 2,638,403 shares of the common stock of Volcano Corporation (“VOLC” or the “Company”) (Nasdaq:VOLC), today sent an open letter http://engagedcapital.com/press/VOLCBODLetter.pdf to the Company’s Board of Directors (the “Board”), filed with the U.S. Securities and Exchange Commission. “It is time for new leadership. We urge the Board to immediately commence a parallel process to evaluate strategic alternatives and conduct a search for CEO candidates with a history of driving profitability and extracting value ...

The Office of Technology Management (OTM) is proud to announce the 2014 awardees of the Illinois Proof-of-Concept (I-POC) Fund. I-POC enables development of projects that demonstrate an innovation’s market viability to potential investors and partners. Stephen Boppart , from the Beckman Institute for Advanced Science and Technology and the College of Engineering, for his Quantitative Pneumatic Otoscope , which uses optical coherence tomography (OCT) to visualize middle ear contents

Infraredx, Inc. , a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that it has received a $25 million equity investment from Nipro Corporation. This investment builds on Infraredx’s exclusive agreement with Nipro for distribution of its TVC Imaging System in Japan, the world’s largest intravascular imaging market. In conjunction with the investment, a member of Nipro’s management team will join Infraredx’s board of directors. “Nipro’s investment in Infraredx underscores the significant potential of our TVC Imaging System to change the standard of care for patients with coronary ...

MedLumics , a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology , has announced the appointment of industry expert Dr. Wolfgang Reim as independent director of its board. Currently a member of the company’s Scientific Advisory Board, Dr. Reim will use his role as independent director to consult on strategic decisions related to product portfolio development, corporate growth and business opportunities.

AngioLight , an early stage, pre-clinical interventional cardiovascular medical device company, has successfully completed an initial animal study of the AngioLight System at Fu Wai Hospital, a leading cardiovascular center located in Beijing. The study paves the way for AngioLight to go forward in China with full-scale animal and clinical testing of the system, which will begin following the anticipated completion of study protocols, hospital review and required China Food and Drug Administration (CFDA) approvals. The AngioLight System is a novel light-based diagnostic catheter designed to provide interventional cardiologists and radiologists with vessel diameter and area measurements that will help improve ...

OptiMedica Corp . has announced that it received a Red Herring 100 North America award, which honors the continent’s most promising private venture technology companies. OptiMedica was selected by Red Herring's editorial staff based on both quantitative and qualitative criteria, such as intellectual property, disruptiveness of the solution in the market, technological advantage, management quality, strategy and market penetration. Alex Vieux, chairman and CEO of Red Herring, presented the awards during a ceremony on May 23, 2013. “Optimization of corneal incision parameters with a femtosecond laser for cataract surgery.” Red Herring 100 Awards are widely recognized as one of ...

Hercules Technology Growth Capital, Inc. (NYSE: HTGC), (“Hercules”), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and cleantech industries, at all stages of development, today announced its first quarter 2013 portfolio update. $10.0 million commitment to NinePoint Medical , a medical device company using a platform technology called Nvision VLE, a non-invasive, endo-microscopic 3-D imaging solution.

Third Rock Ventures, LLC, a venture capital firm focused on building healthcare companies, today announced the final closing of Fund III, raising $516 million in an oversubscribed fund. With Fund III, Third Rock will continue to execute on its strategy of launching, building and supporting transformative healthcare companies. Since its inception, Third Rock has raised more than $1.3 billion, including Fund III, for investments in healthcare companies, with a particular emphasis on innovative product engines.

OptiMedica Corp. has announced the closing of a $35 million growth round of financing. Proceeds will be used to continue the rapid global commercialization of the company’s Catalys® Precision Laser System for cataract surgery, support the development of innovative system enhancements, and fuel a next-generation portfolio of additional products. The round drew participation from all of OptiMedica’s existing venture backers, which include Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital – an esteemed group that together have more than $3.5 trillion under management.

Avinger , Inc., a medical device manufacturer of innovative, multi-functional catheters for crossing CTOs in patients with Peripheral Artery Disease (PAD), announces its CONNECT II global clinical trial results today at the Vascular Interventional Advances (VIVA) Conference 2012 in Las Vegas, Nevada. “These results are impressive and exciting,” said Matt Selmon, M.D. at Heart Hospital of Austin and CONNECT II Trial Co-Principal Investigator. “Having the ability to visually navigate, in real time, inside of the artery during these procedures is going to change the way physicians cross CTOs in order to treat severe PAD.” Dr. Selmon will present the results ...

Global ophthalmic company OptiMedica Corp. has announced clinical data presented at ESCRS 2012 in Milan, Sept. 8 – 12, that has confirmed the unparalleled performance of its Catalys Precision Laser System for cataract surgery. The subject of multiple presentations at the meeting, Catalys has been shown to deliver dramatic improvement in the precision, effectiveness and ease of performing cataract surgery.

This Frost & Sullivan research service titled Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging describes a broad cross section of optical imaging research and clinical technology developments used for early disease detection and therapy guidance. The research service identifies and evaluates key optical imaging segments (optical coherence tomography, hyperspectral imaging, and near-infrared spectroscopy) that are of high interest to investors, estimating time for investment opportunity outcomes. The research service categorizes applications of emerging optical imaging technologies into four distinct areas-ophthalmic imaging, cardiac imaging, neuro imaging, and imaging of the gastrointestinal tracts. The insights provided ...

Global ophthalmic company OptiMedica Corp. has announced that its Catalys Precision Laser System for cataract surgery has been selected as a winner of R&D Magazine’s prestigious R&D 100 award. Selected by an independent judging panel and the editors of R&D Magazine, the R&D 100 awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.

Austin Heart, the largest provider of cardiac and vascular services in Central Texas announces its participation in CONNECT II, a global clinical trial conditionally approved by the FDA that gives physicians access to a sophisticated new imaging technology tool to fight Peripheral Arterial Disease (PAD). The technology, called Ocelot, helps to eliminate the need for bypass surgeries and/or amputations in patients with the disease. Each year, nearly 200,000 amputations occur as a result of PAD and many of them can be avoided.